Tesla Gets Price Target Bumps By Analysts After Strong Q4 Results

Tesla Inc (NASDAQ: TSLA) reported better-than-expected results for its fourth quarter.

Tesla Inc (NASDAQ:TSLA) reported better-than-expected results for its fourth quarter.

Tesla reported quarterly revenue of $24.32 billion, which was up 37% year-over-year, beating a Street estimate of $24.16 billion. The company’s adjusted earnings per share of $1.19 topped a Street estimate of $1.13.

Vehicle production totaled 439,701 units in the fourth quarter, while deliveries amounted to 405,278 electric vehicles.

Tesla shares jumped 7.7% to trade at $155.58 on Thursday.

These analysts made changes to their price targets on Tesla following the release of results.

  • Citigroup boosted the price target on Tesla from $137 to $146. Citigroup analyst Itay Michaeli maintained a Neutral rating on the stock.
  • B of A Securities raised the price target on the stock from $130 to $155. B of A Securities analyst John Murphy maintained the stock with a Neutral.
  • Wolfe Research increased the price target on Tesla from $160 to $185. Wolfe Research analyst Rod Lache maintained the stock with an Outperform.
  • Wells Fargo boosted the price target on Tesla from $130 to $150. Wells Fargo analyst Colin Langan maintained the stock with an Equal-Weight.
  • Cowen & Co. boosted the price target on Tesla from $122 to $140. Cowen & Co. analyst Jeffrey Osborne maintained the stock with a Market Perform.
  • Wedbush raised the price target on Tesla from $175 to $200. Wedbush analyst Daniel Ives maintained the stock with an Outperform.

Check This Out: Ethereum Tops This Major Level; eCash Becomes Top Gainer

Total
0
Shares
Related Posts
Read More

Clover Health Issued An Analysis Titled Clover Assistant Use And Diagnosis, Treatment, And Progression Of Diabetes, Showing Clinician Use Of Clover Assistant Is Associated With Earlier Identification And Management Of Diabetes

Today, Clover Health ("Clover" or "the Company") issued an analysis titled Clover Assistant Use and Diagnosis, Treatment, and Progression of Diabetes, which examines the association between use of the company's flagship

CLOV